Ajanta Pharma has uploaded the audio recording of its earnings call for the first quarter of FY27 (Q1FY27) on its official website. The conference call was held on July 30, 2026, at 4:15 p.m., providing investors and analysts with management commentary on the company’s financial performance for the quarter ended June 30, 2026.

The disclosure was made pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015. This regulation mandates listed entities to provide access to earnings call recordings to ensure transparency and equal information dissemination among stakeholders. The audio file is hosted directly on the company's investor relations portal.

Accessing the Recording

Investors can access the audio recording through the following link provided in the exchange filing:

The company stated that a written transcript of the proceedings will be submitted to the stock exchanges in due course. This transcript will offer a text-based record of the questions asked by analysts and the responses provided by management, complementing the audio recording.

Regulatory Compliance

The filing was signed by Gaurang Chinubhai Shah, Senior Vice President – Legal & Company Secretary at Ajanta Pharma. The notice was simultaneously dispatched to both the BSE Limited and the National Stock Exchange of India, ensuring compliance with listing obligations across both platforms.

This release serves as an informational update for shareholders and market participants who were unable to attend the live call. It ensures that all investors have the opportunity to review management’s perspective on the quarter’s performance, including any guidance or strategic updates discussed during the session.

Ajanta Pharma has fixed August 5, 2026, as the record date for determining shareholders eligible for its first interim dividend of ₹32 per share. The declaration follows the company’s robust Q1FY27 results, where consolidated net profit surged 31% year-on-year to ₹334 crore, while revenue from operations expanded 25% to ₹1,626 crore. This dividend payout, totaling approximately ₹400 crore, underscores management’s confidence in cash generation despite ongoing tax scrutiny and operational headwinds in certain emerging markets.

The Board of Directors approved the dividend on July 30, 2026, pursuant to Regulation 42 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Statutory auditors M/s B S R & Co. LLP issued an unmodified conclusion on the quarterly results. Shareholders holding equity shares on the record date will receive the dividend, with payments scheduled for August 18, 2026, or later. The company operates under an open book closure system, meaning there is no specific book closure period; eligibility is determined solely by the shareholding pattern as of the close of business on the record date.

Q1FY27 Financial Performance

Ajanta Pharma’s top-line growth was broad-based, driven primarily by exceptional performances in its US Generic and Africa Institutional segments. While India’s branded generic business grew 24% to ₹509 crore, Asia saw a 16% decline to ₹255 crore. However, these were offset by a 57% surge in US Generic revenues to ₹487 crore and an 83% jump in Africa Institutional business to ₹70 crore.

Segmental Insights and Operational Efficiency

In India, Ajanta Pharma outperformed the Indian Pharmaceutical Market (IPM) growth rate of 11% with a 15% overall growth. New launches contributed significantly, growing 76% against IPM, while volumes grew 40%. Key therapeutic areas such as Ophthalmology, Dermatology, and Pain Management all exceeded IPM growth rates. The company maintains a strong pipeline with 51 commercialized ANDAs in the US, 17 awaiting FDA approval, and 5 holding tentative approvals.

R&D expenses increased to ₹66 crore (4% of revenue) from ₹56 crore in Q1FY26, reflecting continued investment in formulation capabilities across its seven manufacturing facilities. Despite revenue growth, adjusted EBITDA margin contracted slightly from 29% to 28%, indicating that operating costs rose marginally faster than sales, although absolute earnings power improved significantly.

What the Numbers Show

The divergence between the 25% revenue growth and 31% profit growth highlights improved operational leverage and favorable mix shifts towards higher-margin US generics. The 57% surge in US revenues suggests successful market penetration or volume gains in key molecules. Furthermore, the substantial ₹400 crore dividend payout, representing over 100% of the quarterly net profit, signals strong underlying cash generation capabilities, even as the company navigates tax search operations initiated in August 2025. The impact of these searches remains unquantifiable for Q1FY27, posing a potential future risk to retained earnings.